The phase III NeoADAURA trial is evaluating the use of osimertinib with or without chemotherapy, compared to chemotherapy alone, for resectable stage II-IIIB N2 NSCLC with an EGFR mutation [59]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.